Hyperuricaemia and Gout Pathway

1. Asymptomatic Hyperuricaemia: What Six Bodies Recommend

A raised urate on a health check panel, in a patient who has never had a swollen joint, is the commonest reason a urate-lowering drug is started, and no guideline describes it as standard care. The ACR recommends against it conditionally, certainty graded high: 24 patients treated for three years to prevent one first flare.

These bodies read the same literature and differ on how much evidence a recommendation needs, diverging most where the evidence is thinnest. Japan is narrower than its row suggests: for the patient who has never had a flare, the one thing it recommends with a grade is dietary and lifestyle guidance, not a drug. The reason usually given for treating is cardiovascular and renal protection, and this is the evidence for it.

Urate lowering has not been shown to prevent cardiovascular events and is not offered for that purpose. The renal question is not closed, but the weight of randomised evidence is against a clinically meaningful effect.

2. Diagnosing the Flare, and the Joint That Is Also Septic

EULAR 2018 recommends looking for crystals in synovial fluid or a tophus aspirate in everyone with suspected gout, and strongly in any undiagnosed inflammatory arthritis.

• Where aspiration is not feasible, the named supporting features are a single foot or ankle joint, especially the first metatarsophalangeal, previous similar episodes, pain and swelling worst within 24 hours, erythema, male sex, and cardiovascular disease with hyperuricaemia.
• The diagnosis is not made on hyperuricaemia alone. Roughly 10 per cent of people with gout have a urate below 6 mg/dL while the joint is inflamed. The 2015 criteria want a urate taken off treatment and beyond four weeks from the start of an episode.
• The 2015 ACR/EULAR criteria classify, they do not diagnose. Built for homogeneous trial populations and weighted to specificity, so a score below 8 does not exclude gout in the patient in front of you. This tool prints that caution every time it prints the score.

3. Colchicine and the 0.5 mg Indian Tablet

Every dose in the American literature is built on a 0.6 mg tablet. Indian colchicine is supplied as 0.5 mg. That makes the American regimen of 1.2 mg then 0.6 mg an hour later undeliverable here, and the 0.3 mg renal and interaction doses impossible without quartering a tablet.

• EULAR wrote its regimen in the units India stocks: colchicine within 12 hours of onset, 1 mg loading, then 0.5 mg one hour later, which is two tablets and then one. That is a quotation, not a conversion.
• The evidence for the low dose: a randomised comparison against placebo of 1.8 mg over an hour and 4.8 mg over six hours. Response at 24 hours 37.8 and 32.7 per cent, diarrhoea 23.0 against 76.9 per cent. Each arm was tested against placebo and not against the other, so the two are comparable rather than proven equal.
• Always write the milligrams, never the number of tablets.
• The interaction rule differs by source. The American label permits a reduced dose alongside a strong CYP3A4 or P-glycoprotein inhibitor. EULAR says colchicine should not be given with ciclosporin or clarithromycin, and this tool applies the European rule. Both agree that a patient with renal or hepatic impairment should not have colchicine with such an inhibitor at all, which settles the transplant patient with graft dysfunction.
• Statins and fibrates potentiate colchicine myopathy: a slow, painless, creeping proximal weakness that is routinely attributed to something else.

4. Treat to Target, and the Case Against It

The rationale is physical, not statistical. Monosodium urate crystallises out of solution above roughly 6.8 mg/dL at body temperature, so holding the urate below 6 mg/dL keeps the tissue pool undersaturated and existing deposits dissolve.

• ACR: a target below 6 mg/dL is a strong recommendation, and so is titrating by serial measurements rather than fixed dosing.
• ACP: the evidence is insufficient to show that escalating to a target outweighs the harms of repeated monitoring and escalation, and no study has compared treating to one urate level against another. Its alternative is to escalate on symptoms and stop measuring. Nobody has run the trial that would settle it.
• What the strategy costs in follow-up: a urate every two to four weeks during titration, then twice a year for life. Where that will not happen, the patient stays on 100 mg of allopurinol indefinitely, the dose least likely to reach target and as likely as any to provoke the flares that make patients stop.

5. Allopurinol: Starting Dose, Maintenance Dose, Hypersensitivity

Two separate ideas, and separating them is the useful part. The starting dose is low because a high starting dose is a risk factor for allopurinol hypersensitivity syndrome: 100 mg daily at most, and 50 mg in chronic kidney disease stage 3 or worse. The maintenance dose is whatever reaches the target, and restricting it by creatinine clearance has no evidence behind it.

• The escalation trial: 183 people with gout, 52 per cent with a creatinine clearance below 60 mL/min, randomised to continue a clearance-based dose or to escalate. At 12 months, 69 per cent of the escalation group were below 6 mg/dL against 32 per cent of controls, mean final doses 413 and 288 mg daily. No cases of allopurinol hypersensitivity syndrome in either arm, though the trial was not powered to detect one.
• By renal function at 24 months, in a post hoc analysis of that trial: target reached by 64.3 per cent below a clearance of 30 mL/min, 76.4 per cent between 30 and 60, and 75.0 per cent above 60, differences not significant. Of the 14 patients below a clearance of 30, only 2 needed more than 300 mg daily.
• A live disagreement: EULAR caps the maximum by creatinine clearance and switches agent if target is not reached, while the ACR keeps allopurinol first line in chronic kidney disease and titrates past that cap. The randomised evidence supports the American position. This tool follows it, and says so.

6. HLA-B*58:01 in Indian Populations

One of the strongest drug-genotype associations described: pooled odds ratios of 96.6 in matched-control and 79.3 in population-control studies.

• Who the guidelines say to test. The ACR conditionally recommends testing before allopurinol in patients of Southeast Asian descent, naming Han Chinese, Korean and Thai, and in African American patients: prevalences of 7.4 and 3.8 per cent against 0.7 per cent in white and Hispanic populations. South Asians are not named. APLAR states the rule generically instead: test where the allele prevalence is 5 per cent or more.
• The Indian dataset. Among 130,518 registered Indian stem cell donors in eight linguistic populations, HLA-B*58:01 was in the ten most frequent HLA-B alleles in six of the eight, from 3.20 per cent in Bengali to 6.87 per cent in Malayalam speakers, Kannada next at 5.54 per cent. It did not reach that list in Tamil or Gujarati speakers, so the table gives only a ceiling for those two, below 4.19 and below 3.34 per cent. This tool prints the ceiling rather than a point estimate it does not have.
• Allele frequency is not carrier frequency. The proportion carrying at least one copy is roughly twice the allele frequency, in the region of 6 to 13 per cent. That puts several Indian populations, the southern ones in particular, at or above the threshold at which APLAR would test, and at or above the African American prevalence at which the ACR does.
• What does not exist. No Indian case-control study of the allele and allopurinol-induced severe cutaneous reaction, no Indian carrier frequency in gout patients rather than donors, no Indian cost-effectiveness analysis. The frequency is known; the association in Indians and the value of screening are not. This tool reports the frequency and leaves the decision with the clinician.

7. Febuxostat, Azathioprine and Pyrazinamide

Febuxostat. Two large trials point in opposite directions and the regulators have not converged.

A slide that says Europe advises avoiding febuxostat is out of date. One that says the question is settled in either direction is wrong.

Azathioprine, the interaction that causes marrow failure. Azathioprine becomes 6-mercaptopurine, which xanthine oxidase largely inactivates. Block that enzyme and the thiopurine is diverted into the active nucleotide pathway, producing profound and sometimes fatal myelosuppression.

• The allopurinol label permits the combination with azathioprine reduced to one third to one quarter of usual, with intensive blood count monitoring.
• The American febuxostat label makes azathioprine and mercaptopurine an outright contraindication. The European label calls it not recommended and, if unavoidable, requires the thiopurine at 20 per cent or less of the previous dose.
• So a clinician who switches to febuxostat because the patient is on azathioprine has the interaction exactly backwards. Where azathioprine is kept for cost reasons, moving to mycophenolate is usually safer than manoeuvring around it.

Pyrazinamide, and the urate that does not need treating. Pyrazinamide inhibits tubular secretion of urate.

• The WHO product information calls hyperuricaemia on it very common, at least one in ten, with arthralgia and gout episodes common, between one in a hundred and one in ten. A prospective series found the mean urate rising from 5.1 to 7.4 mg/dL by week 8, hyperuricaemia in 43 per cent and arthralgia in 21.7 per cent.
• The threshold for any corrective treatment is 11 mg/dL. An asymptomatic urate of 8, 9 or 10 on anti-tubercular treatment needs no drug and is not a reason to stop pyrazinamide.
• When correction is indicated the same document excludes xanthine oxidase inhibitors: the lesion is blocked tubular secretion, not overproduction, so allopurinol does not fix it.
• Moderate non-gouty arthralgia responds to symptomatic treatment and resolves. Only persistent arthralgia that genuinely appears gouty justifies stopping the drug.

8. Diet, and the Dal Question

A vegetarian patient with gout is very often told to stop dal, rajma, spinach and mushrooms. The prospective evidence does not support that advice. Every figure below comes from the Health Professionals Follow-up Study, a cohort of American men followed for 12 years. Four separate analyses of it are quoted, drawing on 45,869 to 47,150 men and 730 to 757 confirmed incident cases. Each compares the highest against the lowest quintile of intake unless stated.

APLAR, with Indian authors on the panel, states that there is insufficient evidence to recommend for or against limiting purine-rich food to prevent flares. Counsel an Indian vegetarian patient this way. Keep the dal: it is the main protein in the diet and costs the patient nutritionally to remove. Add curd, buttermilk and low-fat milk, which are protective. Stop the soft drinks and the daily fruit juice. None of it substitutes for a serum urate below 6 mg/dL, which diet alone will not reach. The ACR conditionally recommends against vitamin C supplementation, which does not lower urate to a clinically useful degree.

9. Tumour Lysis, and Uric Acid Stones

Tumour lysis syndrome. Two definitions are in use and a patient may meet one and not the other.

• The two drugs do different things. Allopurinol blocks the formation of new urate, does nothing to what is already circulating, and lets xanthine accumulate, which has its own nephropathy. Rasburicase degrades the urate already there.
• Dose and cost. The licensed rasburicase dose is 0.2 mg/kg intravenously over 30 minutes daily for up to five days, roughly 36,000 rupees a day in India. Two Indian series have published a single fixed dose of 1.5 mg at roughly 6,000 rupees. At Chennai, in a series of 186 patients, it prevented laboratory or clinical tumour lysis in 87 per cent of the prophylactic group. At Bengaluru 60 per cent of 90 patients normalised on it alone, and a further 18 per cent on a second dose. This tool prints that regimen beside the licensed one.
• Rasburicase is contraindicated in G6PD deficiency. The reaction generates hydrogen peroxide and produces acute haemolysis and methaemoglobinaemia. Prevalence across 72 Indian tribal groups runs from 2.3 to 27.0 per cent, overall 7.7 per cent, with no reliable general-population figure. The assay usually does not return inside the window in which the drug is needed.
• Blood drawn after rasburicase goes into a pre-chilled heparin tube, kept in iced water, assayed within four hours, because the enzyme keeps degrading urate in the tube. A normal result from a warm sample is meaningless and falsely reassuring.
• Urinary alkalinisation has been abandoned. It increases calcium phosphate precipitation and reduces xanthine solubility. Hydration is what matters: 2 to 3 litres per square metre per day, urine output above 100 mL per square metre per hour.

Uric acid stones are a disease of acid urine. Aciduria, not hyperuricosuria, is the dominant factor.

• The arithmetic is worth carrying. Uric acid has a pKa of about 5.3 to 5.5, sources vary, so below pH 5.5 most urinary urate is undissociated uric acid, far less soluble than the salt. Of an 800 mg daily load, about 600 mg is undissociated at pH 5.0 and about 100 mg at pH 6.5.
• The pH target differs by purpose, and so do the guidelines. The American Urological Association says raise urine pH to 6.0 for prevention; the European Association of Urology says 7.0 to 7.2 for dissolving a stone that is already there. Above 7.0 solubility does not improve further and calcium phosphate precipitation begins, so over-alkalinisation converts one kind of stone former into another.
• Potassium citrate is the preferred salt at 30 to 60 mEq daily in divided doses, contraindicated in hyperkalaemia and significant renal impairment. Sodium bicarbonate is the alternative in advanced kidney disease, at the cost of a sodium load and higher urinary calcium.
• Allopurinol is not first line for a uric acid stone. It is indicated where the 24-hour urinary uric acid is genuinely high: above 800 mg daily in men and 750 in women by the American convention, above 5 and 4 mmol daily by the European one. The two disagree numerically and neither is reconciled here.
• An Indian caution: citrate on Indian wards is a syrup dosed in millilitres, while every guideline dose is in milliequivalents. Without the citrate content per millilitre of the specific product, a resident cannot reproduce the recommended dose.

10. Indian Epidemiology, and What This Tool Does Not Print

Community surveys put gout prevalence in India remarkably low while biochemical surveys find hyperuricaemia everywhere, and no source consulted for this module reconciles them.

• Household surveys in the Pune region found an age and sex adjusted gout prevalence of 0.06 per cent in an urban population of 8,145 adults and 0.13 per cent in a rural one, against a worldwide range of 0.26 to 1.4 per cent.
• Hyperuricaemia was found in 24.66 per cent of 197,097 subjects screened at 592 Indian camp locations, and in 32.7 per cent of 300 adults in rural Belagavi.
• The explanation may be biology, under-diagnosis in Indian primary care, the difference between a questionnaire and a blood test, or selection into camp cohorts. It is left open because whichever is right changes what to do with a raised urate in an Indian clinic.
• There is no Indian national guideline or society consensus on gout or hyperuricaemia. A 2023 systematic review of high-quality gout guidelines included six, from Europe, the United States, Italy, Britain and Spain, none from India. APLAR 2021 is the closest document with Indian authorship, and this tool cites it for that reason.

What this tool does not print, each an absence stated on purpose rather than a gap filled with something plausible:

• A recommendation to start a urate-lowering drug for asymptomatic hyperuricaemia. It prints what each body says and leaves the decision.
• A carrier frequency for HLA-B*58:01 in Indian gout patients, or a point estimate for Tamil or Gujarati speakers.
• A figure for the urate rise on ethambutol. The effect is real; the primary sources for its mechanism and magnitude could not be obtained.
• A citrate content per millilitre for any Indian syrup, so no millilitre dose can be given.
• A resolution of the febuxostat cardiovascular question, or of the prevalence discordance above.